23andMe Holding Co. Stock News

The genetics specialist notched a double miss with its latest earnings report. It seems this fiscal year will be worse than its predecessor for headline fundamentals.

23andMe Holding Co. (NASDAQ:ME ) Q1 2024 Results Conference Call August 8, 2023 4:30 PM ET Company Participants Katie Watson - Vice President of Communications Anne Wojcicki - Chief Executive Officer

SOUTH SAN FRANCISCO, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access,

Shares of upscale burger chain Shake Shack have wiped out last year's losses, while 23andMe stock set a record low.

Genes are the foundation of human life. They are the code that gives every instruction to our bodies about how to move, digest and think.

23andMe entered its IPO with two down years on revenue but has since reclaimed low double-digit growth. Throughout this time, however, the company has not made identifiable progress toward profitabili

23andMe Holding Co. (NASDAQ:ME ) Q4 2023 Results Conference Call May 25, 2023 4:30 PM ET Company Participants Maeve Conneighton - Investor Relations at Argo Partners Anne Wojcicki - Chief Executive Of

Artificial intelligence is becoming an important value-add for collaborations. Some companies are pursuing collaboration-targeted business models.

Accurately predicting when you'll die or be stricken by disease is part of retirement planning. It's possible with DNA testing.

High-risk penny stocks have long tempted investors with the potential for significant returns. However, it is crucial to acknowledge the inherent risks associated with these speculative investments.

SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, announced today that it will report fi

23andMe CEO Anne Wojcicki joins Yahoo Finance Live's Brian Sozzi from the 26th annual Milken Institute Global Conference in Beverly Hills, CA, to discuss the next phase of growth for 23andMe, partneri

23andMe is known around the world for its ancestry DNA genetic testing service. The company's pivot into therapeutics seems attractive.

Artificial intelligence tools could lead to tremendous growth for some companies. 23andMe is already turning its genetic data into pipeline projects at a rapid clip.

23andMe has made many strategic acquisitions that have helped the company expand and grow. The genomics industry as a whole is expected to have rapid growth in the future due to the convenience of tes